Latest Disease-modifying antirheumatic drug Stories
Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint.
NUTLEY, N.J., Sept. 18 /PRNewswire/ -- Roche today announced that the U.S.
Pipex Pharmaceuticals, Inc.
Hollis-Eden Pharmaceuticals has started a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate Triolex in patients diagnosed with rheumatoid arthritis and receiving a stable dose of methotrexate, the current standard of care in rheumatoid arthritis.
Roche has announced that the arthritis advisory committee of the FDA has recommended approval of Actemra, a novel interleukin-6 receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis.
NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S.
The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
Lux Biosciences today announced the completion of enrollment for the landmark LUMINATE (Luveniq Uveitis Multicenter Investigation of a New Approach to TrEatment) pivotal clinical trial program, which is investigating the use of LUVENIQ(TM) (voclosporin; previously designated LX211) as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis.
In patients with rheumatoid arthritis, use of disease-modifying antirheumatic drugs, or DMARDs, seems to lower the increased risk of cardiovascular disease associated with rheumatoid arthritis, research suggests.
NEW YORK (Reuters Health) - Even if an initial course of methotrexate for the treatment of rheumatoid arthritis (RA) gives disappointing results, persistence may pay off. A second course may be more successful, researchers report.
- A serpent whose bite was fabled to produce intense thirst.